m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00587)
Target Name 40S ribosomal protein S6 (S6)
Synonyms
Phosphoprotein NP33; Small ribosomal subunit protein eS6
    Click to Show/Hide
Gene Name S6
Chromosomal Location 9p22.1
Family Eukaryotic ribosomal protein eS6 family
Function
Component of the 40S small ribosomal subunit. Plays an important role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA.
    Click to Show/Hide
Gene ID 6194
Uniprot ID
RS6_HUMAN
HGNC ID
HGNC:10429
Ensembl Gene ID
ENSG00000137154
KEGG ID
hsa:6194
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
S6 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing protein 2 (YTHDC2) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary YTHDC2 promotes radiotherapy resistance of NPC cells by activating the IGF1R/ATK/40S ribosomal protein S6 (S6) signaling axis and serves as a potential therapeutic target in radiosensitization of NPC cells.
Target Regulation Up regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
In-vitro Model HK1-IRR (HK1-IRR (HK1-ionizing radiation radioresistent cell line) was derived from HK1 after a prolonged exposure of irradiation.HK1, a generous gift from Prof. Ya Cao (Cancer Research Institute, Central South University), was established from a recurrent nasopharynx carcinoma of a Chinese 17-year-old male patient)
NPC/HK1 Nasopharyngeal carcinoma Homo sapiens CVCL_7084
CNE2-IRR (CNE2-IRR (CNE2-ionizing radiation radioresistent cell line) was derived from CNE2 after a prolonged exposure of irradiation)
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model 2 × 106 cells resuspended in 50 uL of Matrigel (Corning) were subcutaneously injected into 4-6 weeks old male nude mice. When tumor volumes reached 150-200 mm3, animals were divided into control group and radiotherapy group. In the radiotherapy group, tumors were treated with a single irradiation (4 Gy) when tumor volumes reached approximately 150-200 mm3. The tumor stopped growing in the next few days and then restarted growth.
Nasopharyngeal carcinoma [ICD-11: 2B6B]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary YTHDC2 promotes radiotherapy resistance of NPC cells by activating the IGF1R/ATK/40S ribosomal protein S6 (S6) signaling axis and serves as a potential therapeutic target in radiosensitization of NPC cells.
Responsed Disease Nasopharyngeal carcinoma [ICD-11: 2B6B]
Target Regulator YTH domain-containing protein 2 (YTHDC2) READER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model HK1-IRR (HK1-IRR (HK1-ionizing radiation radioresistent cell line) was derived from HK1 after a prolonged exposure of irradiation.HK1, a generous gift from Prof. Ya Cao (Cancer Research Institute, Central South University), was established from a recurrent nasopharynx carcinoma of a Chinese 17-year-old male patient)
NPC/HK1 Nasopharyngeal carcinoma Homo sapiens CVCL_7084
CNE2-IRR (CNE2-IRR (CNE2-ionizing radiation radioresistent cell line) was derived from CNE2 after a prolonged exposure of irradiation)
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model 2 × 106 cells resuspended in 50 uL of Matrigel (Corning) were subcutaneously injected into 4-6 weeks old male nude mice. When tumor volumes reached 150-200 mm3, animals were divided into control group and radiotherapy group. In the radiotherapy group, tumors were treated with a single irradiation (4 Gy) when tumor volumes reached approximately 150-200 mm3. The tumor stopped growing in the next few days and then restarted growth.
References
Ref 1 m(6)A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis. Front Oncol. 2020 Jul 31;10:1166. doi: 10.3389/fonc.2020.01166. eCollection 2020.